Lilly CEO says weight-loss drug shortage to end 'very soon', Bloomberg
News reports
Send a link to a friend
[August 02, 2024]
(Reuters) - U.S. drugmaker Eli Lilly expects its blockbuster
weight-loss drug to officially come out of shortage in the United States
in coming days, Bloomberg News reported on Thursday, citing an interview
with the company's CEO, David Ricks.
Lilly's drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound
for weight management, will cease to be in shortage "very soon," CEO
David Ricks said in an interview with Bloomberg in Paris.
The U.S. Food and Drug Administration's website lists some doses of
Mounjaro and Zepbound as being in limited supply. Mounjaro has been on
the FDA's shortage list since late 2022.
The health regulator said it has no further comments to provide beyond
what is available on its drug shortages list, while Lilly did not
immediately respond to a request for comment.
The agency generally assesses whether all backorders for the drug have
been filled and supply is meeting or exceeding demand before removing a
drug from its shortage list.
Lilly said in April that it expects supply of Zepbound to remain "quite
tight" in the near and midterm as it ramps up capacity.
[to top of second column]
|
A box of Mounjaro, a tirzepatide injection drug used for treating
type 2 diabetes and made by Lilly is seen at Rock Canyon Pharmacy in
Provo, Utah, U.S. March 29, 2023. REUTERS/George Frey/File Photo
Eli Lilly and Danish rival Novo
Nordisk are racing to increase production in a weight-loss drug
market estimated to reach about $150 billion by early 2030s. Both
the companies' obesity treatments belong to a class of drugs
originally developed for diabetes known as GLP-1 agonists.
GLP-1 drugs have been shown to help patients lose on average as much
as 20% of their weight, fueling unparalleled demand.
Novo makes the diabetes drug Ozempic and its weight-loss equivalent
Wegovy.
Separately, Lilly reported earlier on Thursday that Zepbound helped
reduce the risk of hospitalization, death and other outcomes for
obese adults with a common type of heart failure.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |